Art. -Nr.: HY-B0451A

Dopamine hydrochloride

(Synonyms: ASL279)

29 Cited Publications

Kundenbewertung

Based on 29 publication(s) in Google Scholar

Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body. Dopamine hydrochloride (ASL279) acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.79%
CAS. Nr.: 62-31-7
Formel: C₈H₁₂ClNO₂
Molecular Weight:189.64

Speicherung:

4°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Dopamine hydrochloride Chemical Structure

CAS. Nr.: 62-31-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (29)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body^[1]. Dopamine hydrochloride (ASL279) acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis^[1].

IC₅₀ & Target

Microbial Metabolite

D2 Dopamine Receptor

Alle Dopamine Receptor Isoform-spezifische Produkte anzeigen :

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	209 nM Compound: dopamine	Agonist activity at human dopamine D2 receptor expressed in CHO cells by [35S]GTPgammaS binding assay Agonist activity at human dopamine D2 receptor expressed in CHO cells by [35S]GTPgammaS binding assay	[PMID: 20146482]
CHO	EC₅₀	4.76 nM Compound: dopamine	Agonist activity at human dopamine D3 receptor expressed in CHO cells by [35S]GTPgammaS binding assay Agonist activity at human dopamine D3 receptor expressed in CHO cells by [35S]GTPgammaS binding assay	[PMID: 20146482]
CHO	EC₅₀	227 nM Compound: DA	Agonist activity at human cloned dopamine D2 receptor expressed in CHO cells by [35S]GTPgammaS binding assay Agonist activity at human cloned dopamine D2 receptor expressed in CHO cells by [35S]GTPgammaS binding assay	[PMID: 22642365]
CHO	EC₅₀	8.57 nM Compound: DA	Agonist activity at human cloned dopamine D3 receptor expressed in CHO cells by [35S]GTPgammaS binding assay Agonist activity at human cloned dopamine D3 receptor expressed in CHO cells by [35S]GTPgammaS binding assay	[PMID: 22642365]
CHO	EC₅₀	240 nM Compound: Dopamine	Agonist activity at human cloned dopamine D2 receptor expressed in CHO cells by [35S]GTP gammaS binding assay Agonist activity at human cloned dopamine D2 receptor expressed in CHO cells by [35S]GTP gammaS binding assay	[PMID: 23275802]
CHO	EC₅₀	5.8 nM Compound: Dopamine	Agonist activity at human cloned dopamine D3 receptor expressed in CHO cells by [35S]GTP gammaS binding assay Agonist activity at human cloned dopamine D3 receptor expressed in CHO cells by [35S]GTP gammaS binding assay	[PMID: 23275802]
CHO	EC₅₀	227 nM Compound: DA	Agonist activity at human dopamine D2L receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis Agonist activity at human dopamine D2L receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis	[PMID: 23623679]
CHO	EC₅₀	7.64 nM Compound: DA	Agonist activity at human dopamine D3 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis Agonist activity at human dopamine D3 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis	[PMID: 23623679]
CHO	EC₅₀	36 nM Compound: Dopamine	Agonist activity at human dopamine D2 receptor expressed in CHO cells assessed as increase of forskolin-induced cAMP production after 20 mins Agonist activity at human dopamine D2 receptor expressed in CHO cells assessed as increase of forskolin-induced cAMP production after 20 mins	[PMID: 24296012]
CHO	EC₅₀	39 nM Compound: Dopamine	Agonist activity at human recombinant dopamine D1 receptor expressed in CHO cells assessed as cAMP production after 20 mins Agonist activity at human recombinant dopamine D1 receptor expressed in CHO cells assessed as cAMP production after 20 mins	[PMID: 24296012]
CHO	EC₅₀	183 nM Compound: DA	Agonist activity at human D2 receptor expressed in CHO cells by [35S]GTPgammaS binding assay Agonist activity at human D2 receptor expressed in CHO cells by [35S]GTPgammaS binding assay	[PMID: 26555041]
CHO	EC₅₀	5.34 nM Compound: DA	Agonist activity at human D3 receptor expressed in CHO cells by [35S]GTPgammaS binding assay Agonist activity at human D3 receptor expressed in CHO cells by [35S]GTPgammaS binding assay	[PMID: 26555041]
CHO	EC₅₀	376 nM Compound: Dopamine	Agonist activity at human D2 dopamine receptor expressed in CHO cells by [35S]GTPgammaS binding assay Agonist activity at human D2 dopamine receptor expressed in CHO cells by [35S]GTPgammaS binding assay	[PMID: 27591013]
CHO	EC₅₀	7.26 nM Compound: Dopamine	Agonist activity at human D3 dopamine receptor expressed in CHO cells by [35S]GTPgammaS binding assay Agonist activity at human D3 dopamine receptor expressed in CHO cells by [35S]GTPgammaS binding assay	[PMID: 27591013]
CHO-K1	EC₅₀	1425 nM Compound: Dopamine	Agonist activity at rat dopamine D2short receptor expressed in CHO-K1 cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting Agonist activity at rat dopamine D2short receptor expressed in CHO-K1 cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting	[PMID: 19454369]
CHO-K1	EC₅₀	1.8 nM Compound: Dopamine	Agonist activity at dopamine D3 receptor (unknown origin) expressed in CHOK1 cells coexpressing Galpha15 by FLIPR assay Agonist activity at dopamine D3 receptor (unknown origin) expressed in CHOK1 cells coexpressing Galpha15 by FLIPR assay	[PMID: 23675993]
CHO-K1	EC₅₀	6.7 nM Compound: Dopamine	Agonist activity at dopamine D2 receptor (unknown origin) expressed in CHOK1 cells coexpressing Galpha15 by FLIPR assay Agonist activity at dopamine D2 receptor (unknown origin) expressed in CHOK1 cells coexpressing Galpha15 by FLIPR assay	[PMID: 23675993]
CHO-K1	EC₅₀	0.69 nM Compound: Dopamine	Agonist activity at D2 receptor (unknown origin) expressed in CHOK1 cells co-expressing G-alpha 15 by fluo-4 dye based FLIPR assay Agonist activity at D2 receptor (unknown origin) expressed in CHOK1 cells co-expressing G-alpha 15 by fluo-4 dye based FLIPR assay	[PMID: 27487565]
COS-7	IC₅₀	111 nM Compound: Dopamine	Displacement of [3H]nemonapride from Rattus norvegicus (rat) wild type dopamine D3 receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting Displacement of [3H]nemonapride from Rattus norvegicus (rat) wild type dopamine D3 receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting	10.1007/s00044-004-0006-x
COS-7	IC₅₀	124 nM Compound: Dopamine	Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D3 trunk/D3 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D3 trunk/D3 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting	10.1007/s00044-004-0006-x
COS-7	IC₅₀	3140 nM Compound: Dopamine	Displacement of [3H]nemonapride from Rattus norvegicus (rat) wild type dopamine D2 receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting Displacement of [3H]nemonapride from Rattus norvegicus (rat) wild type dopamine D2 receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting	10.1007/s00044-004-0006-x
COS-7	IC₅₀	3260 nM Compound: Dopamine	Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D2 trunk/D2 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D2 trunk/D2 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting	10.1007/s00044-004-0006-x
COS-7	IC₅₀	483 nM Compound: Dopamine	Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D3 trunk/D2 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D3 trunk/D2 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting	10.1007/s00044-004-0006-x
COS-7	IC₅₀	582 nM Compound: Dopamine	Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D2 trunk/D3 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D2 trunk/D3 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting	10.1007/s00044-004-0006-x
HEK293	EC₅₀	1.1 nM Compound: Dopamine	In vitro effective concentration tested on HEK293 cells co-transfected with rat Dopamine receptor D2 using FLIPR assay In vitro effective concentration tested on HEK293 cells co-transfected with rat Dopamine receptor D2 using FLIPR assay	[PMID: 15239663]
HEK293	EC₅₀	18 nM Compound: Dopamine	In vitro effective concentration tested on HEK293 cells co-transfected with human Dopamine receptor D2 using FLIPR assay In vitro effective concentration tested on HEK293 cells co-transfected with human Dopamine receptor D2 using FLIPR assay	[PMID: 15239663]
HEK293	EC₅₀	2.2 nM Compound: Dopamine	In vitro effective concentration tested on HEK293 cells co-transfected with human Dopamine receptor D4 using FLIPR assay In vitro effective concentration tested on HEK293 cells co-transfected with human Dopamine receptor D4 using FLIPR assay	[PMID: 15239663]
HEK293	EC₅₀	2.4 nM Compound: Dopamine	In vitro effective concentration tested on HEK293 cells co-transfected with rat Dopamine receptor D4 using FLIPR assay In vitro effective concentration tested on HEK293 cells co-transfected with rat Dopamine receptor D4 using FLIPR assay	[PMID: 15239663]
HEK293	EC₅₀	2.7 nM Compound: Dopamine	In vitro effective concentration tested on HEK293 cells co-transfected with ferret Dopamine receptor D4 using FLIPR assay In vitro effective concentration tested on HEK293 cells co-transfected with ferret Dopamine receptor D4 using FLIPR assay	[PMID: 15239663]
HEK293	EC₅₀	8 nM Compound: Dopamine	In vitro effective concentration tested on HEK293 cells co-transfected with ferret Dopamine receptor D2 using FLIPR assay In vitro effective concentration tested on HEK293 cells co-transfected with ferret Dopamine receptor D2 using FLIPR assay	[PMID: 15239663]
HEK293	EC₅₀	1.1 nM Compound: dopamine	Agonist activity at rat D2 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR Agonist activity at rat D2 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR	[PMID: 17149874]
HEK293	EC₅₀	18 nM Compound: dopamine	Agonist activity at human D2 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR Agonist activity at human D2 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR	[PMID: 17149874]
HEK293	EC₅₀	2.2 nM Compound: dopamine	Agonist activity at human D4.4 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR Agonist activity at human D4.4 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR	[PMID: 17149874]
HEK293	EC₅₀	2.4 nM Compound: dopamine	Agonist activity at rat D4 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR Agonist activity at rat D4 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR	[PMID: 17149874]
HEK293	EC₅₀	2.7 nM Compound: dopamine	Agonist activity at ferret D4 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR Agonist activity at ferret D4 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR	[PMID: 17149874]
HEK293	EC₅₀	8 nM Compound: dopamine	Agonist activity at ferret D2 receptor in HEK293 cells coexpressing Galphaqo5 by FLIPR Agonist activity at ferret D2 receptor in HEK293 cells coexpressing Galphaqo5 by FLIPR	[PMID: 17149874]
HEK293	EC₅₀	37 nM Compound: 1, DA	Agonist activity at human dopamine D1 receptor expressed in HEK293 cells assessed as cAMP accumulation after 15 mins Agonist activity at human dopamine D1 receptor expressed in HEK293 cells assessed as cAMP accumulation after 15 mins	[PMID: 21862338]
HEK293	IC₅₀	1 μM Compound: dopamine	Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis	[PMID: 24325578]
HEK293	IC₅₀	1 x 10^-4 M Compound: dopamine	Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis	[PMID: 24325578]
HEK293	EC₅₀	470 nM Compound: Dopamine	Agonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells co-expressing Galphai2 after 30 mins by [35S]GTPgammaS binding assay Agonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells co-expressing Galphai2 after 30 mins by [35S]GTPgammaS binding assay	[PMID: 24831693]
HEK293	EC₅₀	9.3 nM Compound: Dopamine	Agonist activity at human dopamine D3 receptor transiently expressed in HEK293 cells co-expressing Galphao1 after 30 mins by [35S]GTPgammaS binding assay Agonist activity at human dopamine D3 receptor transiently expressed in HEK293 cells co-expressing Galphao1 after 30 mins by [35S]GTPgammaS binding assay	[PMID: 24831693]
HEK293	EC₅₀	0.8 nM Compound: 1; DA	Agonist activity at D2R (unknown origin) expressed in HEK293 cells assessed as effect on cAMP accumulation incubated for 10 mins by Gi-cAMP Glosensor assay Agonist activity at D2R (unknown origin) expressed in HEK293 cells assessed as effect on cAMP accumulation incubated for 10 mins by Gi-cAMP Glosensor assay	[PMID: 31098001]
HEK293	EC₅₀	1.8 nM Compound: 1; DA	Agonist activity at D4R (unknown origin) expressed in HEK293 cells assessed as effect on cAMP accumulation incubated for 10 mins by Gi-cAMP Glosensor assay Agonist activity at D4R (unknown origin) expressed in HEK293 cells assessed as effect on cAMP accumulation incubated for 10 mins by Gi-cAMP Glosensor assay	[PMID: 31098001]
HEK293	EC₅₀	1400 nM Compound: 1; DA	Agonist activity at wild type human D1R expressed in HEK293 cells assessed as effect on beta-arrestin2 recruitment by PRESTO-Tango beta-arrestin2 recruitment assay Agonist activity at wild type human D1R expressed in HEK293 cells assessed as effect on beta-arrestin2 recruitment by PRESTO-Tango beta-arrestin2 recruitment assay	[PMID: 31098001]
HEK293	EC₅₀	2 nM Compound: 1; DA	Agonist activity at D5R (unknown origin) expressed in HEK293 cells assessed as effect on cAMP accumulation incubated for 10 mins by Gs-cAMP Glosensor assay Agonist activity at D5R (unknown origin) expressed in HEK293 cells assessed as effect on cAMP accumulation incubated for 10 mins by Gs-cAMP Glosensor assay	[PMID: 31098001]
HEK293	EC₅₀	44 nM Compound: 1; DA	Agonist activity at wild type human D1R expressed in HEK293 cells assessed as effect on cAMP accumulation incubated for 10 mins by Gs-cAMP Glosensor assay Agonist activity at wild type human D1R expressed in HEK293 cells assessed as effect on cAMP accumulation incubated for 10 mins by Gs-cAMP Glosensor assay	[PMID: 31098001]
HEK293	EC₅₀	1.1 nM Compound: DA	Agonist activity at RLuc8-fused Go-coupled human D3R expressed in HEK293 cells untagged beta1 and mVenus-tagged gamma2 measured after 5 mins in presence of coelenterazine H by BRET assay Agonist activity at RLuc8-fused Go-coupled human D3R expressed in HEK293 cells untagged beta1 and mVenus-tagged gamma2 measured after 5 mins in presence of coelenterazine H by BRET assay	[PMID: 32342685]
HEK293	EC₅₀	2.3 nM Compound: DA	Agonist activity at RLuc8-fused human D3R expressed in HEK293 cells co-expressing N-terminal Venus-tagged beta-arrestin2 and GRK3 assessed as induction of beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay Agonist activity at RLuc8-fused human D3R expressed in HEK293 cells co-expressing N-terminal Venus-tagged beta-arrestin2 and GRK3 assessed as induction of beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay	[PMID: 32342685]
HEK293	EC₅₀	3.5 nM Compound: DA	Agonist activity at human D3R expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP production measured after 5 mins in presence of beta-adrenergic blocker propranolol and coelenterazine H by CAMYEL BRET assay Agonist activity at human D3R expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP production measured after 5 mins in presence of beta-adrenergic blocker propranolol and coelenterazine H by CAMYEL BRET assay	[PMID: 32342685]
HEK293	EC₅₀	33 nM Compound: DA	Agonist activity at RLuc8-fused human D3R Y365A mutant expressed in HEK293 cells co-expressing N-terminal Venus-tagged beta-arrestin2 and GRK3 assessed as induction of beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRE Agonist activity at RLuc8-fused human D3R Y365A mutant expressed in HEK293 cells co-expressing N-terminal Venus-tagged beta-arrestin2 and GRK3 assessed as induction of beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRE	[PMID: 32342685]
HEK293	EC₅₀	55 nM Compound: DA	Agonist activity at RLuc8-fused human D3R Y198A mutant expressed in HEK293 cells co-expressing N-terminal Venus-tagged beta-arrestin2 and GRK3 assessed as induction of beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRE Agonist activity at RLuc8-fused human D3R Y198A mutant expressed in HEK293 cells co-expressing N-terminal Venus-tagged beta-arrestin2 and GRK3 assessed as induction of beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRE	[PMID: 32342685]
HEK293	EC₅₀	820 nM Compound: DA	Agonist activity at RLuc8-fused human D3R Y198A/Y365A double mutant expressed in HEK293 cells co-expressing N-terminal Venus-tagged beta-arrestin2 and GRK3 assessed as induction of beta-arrestin2 recruitment measured after 5 mins in presence of coelentera Agonist activity at RLuc8-fused human D3R Y198A/Y365A double mutant expressed in HEK293 cells co-expressing N-terminal Venus-tagged beta-arrestin2 and GRK3 assessed as induction of beta-arrestin2 recruitment measured after 5 mins in presence of coelentera	[PMID: 32342685]
HEK293	EC₅₀	46 μM Compound: dopamine	Inhibition of the Dopamine transporter (DAT, SLC6A3) as assessed by GPCR-mediated changes in cell morphology using the impedance-based transporter activity through receptor activation (TRACT) assay in HEK-293 JumpIN-SLC6A3 cells (PubChem AID: 1745858) Inhibition of the Dopamine transporter (DAT, SLC6A3) as assessed by GPCR-mediated changes in cell morphology using the impedance-based transporter activity through receptor activation (TRACT) assay in HEK-293 JumpIN-SLC6A3 cells (PubChem AID: 1745858)	[PMID: 33446713]
HEK293	EC₅₀	20 μM Compound: DA	Inhibition of the Norepinephrine transporter (NET, SLC6A2) as assessed by GPCR-mediated changes in cell morphology using the impedance-based transporter activity through receptor activation (TRACT) assay in HEK-293 JumpIN-SLC6A2 cells (PubChem AID: 174586 Inhibition of the Norepinephrine transporter (NET, SLC6A2) as assessed by GPCR-mediated changes in cell morphology using the impedance-based transporter activity through receptor activation (TRACT) assay in HEK-293 JumpIN-SLC6A2 cells (PubChem AID: 174586	[PMID: 34112854]
HEK-293T	EC₅₀	1.8 nM Compound: DA	Agonist activity at human D3 receptor transfected in HEK293T cells by BRET based G0 activation assay Agonist activity at human D3 receptor transfected in HEK293T cells by BRET based G0 activation assay	[PMID: 27035329]
HEK-293T	EC₅₀	5 nM Compound: DA	Agonist activity at human D2 receptor transfected in HEK293T cells by BRET based G0 activation assay Agonist activity at human D2 receptor transfected in HEK293T cells by BRET based G0 activation assay	[PMID: 27035329]
HEK-293T	EC₅₀	160 nM Compound: Dopamine	Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 and GRK2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 and GRK2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay	[PMID: 28489379]
HEK-293T	EC₅₀	200 nM Compound: Dopamine	Agonist activity at human D2S receptor expressed in HEK293T cell membranes coexpressing Galphao1 assessed as induction of nucleotide exchange preincubated for 30 mins followed by addition of [35S]GTPgammaS measured after 30 mins by [35S]GTPgammaS binding Agonist activity at human D2S receptor expressed in HEK293T cell membranes coexpressing Galphao1 assessed as induction of nucleotide exchange preincubated for 30 mins followed by addition of [35S]GTPgammaS measured after 30 mins by [35S]GTPgammaS binding	[PMID: 28489379]
HEK-293T	EC₅₀	390 nM Compound: Dopamine	Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay	[PMID: 28489379]
MRC5	IC₅₀	68.9 μM Compound: 35	Cytotoxicity against human MRC5 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 27155468]
RAW264.7	EC₅₀	18 μM Compound: 11	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs by Griess assay	[PMID: 29517238]

In Vitro

Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) strongly stimulates human umbilical vein endothelial cells (HUVECs) proliferation. The stimulatory effect of VPF/VEGF is abrogated by Dopamine (1 μM; 24hours)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

HUVECs
Concentration:

1 µM
Incubation Time:

24 hours
Result:

Inhibited VPF/VEGF-induced HUVEC proliferation specifically through its D2 receptor.

In Vivo

Dopamine (50 mg/kg; i.p. injection; days 1-7) strongly and selectively inhibits the vascular permeabilizing and angiogenic activities of VPF/VEGF^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Syngeneic C3Heb/FeJ mice with MOT ascites tumors^[2]
Dosage:

50 mg/kg
Administration:

I.p. injection; 7 days
Result:

Corresponding to ~5% of the median lethal dose (LD₅₀) in mice) beginning at 24 hours after tumor-cell injection and continuing daily for 7 days.

Chemical Information

CAS. Nr. 62-31-7
Appearance Solid
Molecular Weight 189.64
Formel C₈H₁₂ClNO₂
Color White to off-white
SMILES

OC1=CC=C(CCN)C=C1O.Cl
Synonyms

ASL279
Structure Classification
- Phenols
- Polyphenols
Initial Source
- Microorganisms
- Endogenous metabolite
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Publications (29)

All Histological Imaging/Staining

Sort by:

Journal Impact Factor

Cell Res

Light sensing enhances thermotolerance and competitive fitness via serotonergic signaling in an eyeless organism. [Abstract]

2026 Apr;36(4):286-299. PMID: 41764323
Immunity

Spatiotemporal dynamics of CXCL10 encode contextual immune information revealed by the genetically encoded fluorescent sensor. [Abstract]

2025 Sep 9;58(9):2320-2335.e9. PMID: 40818452
Nat Commun

Drug inhibition and substrate transport mechanisms of human VMAT2. [Abstract]

2025 Jan 2;16(1):323. PMID: 39747030
Nat Commun

AAV-delivered muscone-induced transgene system for treating chronic diseases in mice via inhalation. [Abstract]

2024 Feb 6;15(1):1122. PMID: 38321056
J Clin Invest

A midbrain-cortical circuit mediated by a claustrum neuronal ensemble orchestrates drug-paired context memory processing. [Abstract]

2026 Jan 15;136(5):e196944. PMID: 41538288
Sci Adv

Surficial nano-deposition locoregionally yielding bactericidal super CAR-macrophages expedites periprosthetic osseointegration. [Abstract]

2023 Jun 2;9(22):eadg3365. PMID: 37256944
Int J Biol Macromol

Oral pH-responsive sodium alginate microspheres co-delivering Musca domestica cecropin and eugenol for anti-inflammatory therapy in sepsis. [Abstract]

2026 May:362:152049. PMID: 41997316
Int J Nanomedicine

Polydopamine-Based Nanoparticles for Synergistic Chemotherapy of Prostate Cancer. [Abstract]

2024 Jul 3:19:6717-6730. PMID: 38979530
Phytother Res

Hordenine improves Parkinsonian-like motor deficits in mice and nematodes by activating dopamine D2 receptor-mediated signaling. [Abstract]

2023 Aug;37(8):3296-3308. PMID: 36883794
ACS Appl Mater Interfaces

Multifunctional Inorganic-Nanosheets-Based Nanohydrogel for Periodontal Bone Regeneration via Antibacterial and Anti-Ferroptotic Immunomodulation. [Abstract]

2025 Nov 26;17(47):64149-64167. PMID: 41250788
Anal Chem

High-Throughput Reactive Desorption Electrospray Ionization Mass Spectrometry for Targeted Derivatization and Analysis of Poorly Ionized Small Molecules. [Abstract]

2026 Jun 16;98(23):16962-16970. PMID: 42223360
Results Chem

2026 Apr 21;26:103342.
Eur J Pharmacol

Establishment of a novel model of depression caused by olfactory dysfunction through intranasal administration of 3-methylindole. [Abstract]

2026 Jul 10:1029:178996. PMID: 42167669
Eur J Pharmacol

Parishin A alleviates insomnia by regulating hypothalamic-pituitary-adrenal axis homeostasis and directly targeting orexin receptor OX2. [Abstract]

2025 Jul 5:998:177498. PMID: 40064224
Eur J Pharmacol

A novel dopamine D2 receptor-NR2B protein complex might contribute to morphine use disorders. [Abstract]

2023 Dec 15:961:176174. PMID: 37939993
Int J Mol Sci

Polydopamine Copolymers for Stable Drug Nanoprecipitation. [Abstract]

2022 Oct 17;23(20):12420. PMID: 36293275
Microchem J

2025 Dec 18;220:116650.
Microorganisms

Dopamine Is a Key Regulatory Molecule for Escherichia coli and May Serve as a Xenosiderophore. [Abstract]

2026 Jan 30;14(2):327. PMID: 41753614
Structure

2026 Jun 8.
J Solid State Electrochem

2025 Jan 17.
J Biomed Mater Res B Appl Biomater

Immunomodulation and Oxidative Stress Mitigation Mediate Enhanced Bone Regeneration by a Platelet-Rich Plasma-Loaded Composite Scaffold. [Abstract]

2026 Jan;114(1):e70037. PMID: 41555765
New J Chem

03 Aug 2022.
SSRN

2026 Jun 16.
Elife

Dopamine and its receptor DcDop2 are involved in the coevolution between ' Candidatus Liberibacter asiaticus' and Diaphorina citri. [Abstract]

2026 Jun 22:15:RP109081. PMID: 42329805
bioRxiv

2026 Mar 7.
bioRxiv

2025 Oct 12.
bioRxiv

2025 Oct 22.
bioRxiv

2023 Oct 13.

Dopamine hydrochloride purchased from MedChemExpress. Usage Cited in: bioRxiv. 2023 Oct 13.

Representative images of fluorescence of TR-D3 in the anterior and posterior brain sections, brainstem, the cervical, thoracic and lumbar spinal cord, and liver in control and in the presence of dopamine (DA).
Biomed Pharmacother

Dopamine delays articular cartilage degradation in osteoarthritis by negative regulation of the NF-κB and JAK2/STAT3 signaling pathways. [Abstract]

2019 Nov:119:109419. PMID: 31563117

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : ≥ 50 mg/mL (263.66 mM)

DMSO : 50 mg/mL (263.66 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.2731 mL

26.3657 mL

52.7315 mL

5 mM

1.0546 mL

5.2731 mL

10.5463 mL

10 mM

0.5273 mL

2.6366 mL

5.2731 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (600 KB)
- English - EN (600 KB)
- Français - FR (600 KB)
- Deutsch - DE (600 KB)
- Norwegian - NO (600 KB)
- Español - ES (600 KB)
- Swedish - SV (600 KB)
- Italian - IT (600 KB)
- Korean - KR (600 KB)
- Portuguese - PT (600 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Juárez Olguín H, et al. The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress. Oxid Med Cell Longev. 2016;2016:9730467. [Content Brief]

[2]. Basu S, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med. 2001 May;7(5):569-74. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	5.2731 mL	26.3657 mL	52.7315 mL	131.8287 mL
	5 mM	1.0546 mL	5.2731 mL	10.5463 mL	26.3657 mL
	10 mM	0.5273 mL	2.6366 mL	5.2731 mL	13.1829 mL
	15 mM	0.3515 mL	1.7577 mL	3.5154 mL	8.7886 mL
	20 mM	0.2637 mL	1.3183 mL	2.6366 mL	6.5914 mL
	25 mM	0.2109 mL	1.0546 mL	2.1093 mL	5.2731 mL
	30 mM	0.1758 mL	0.8789 mL	1.7577 mL	4.3943 mL
	40 mM	0.1318 mL	0.6591 mL	1.3183 mL	3.2957 mL
	50 mM	0.1055 mL	0.5273 mL	1.0546 mL	2.6366 mL
	60 mM	0.0879 mL	0.4394 mL	0.8789 mL	2.1971 mL
	80 mM	0.0659 mL	0.3296 mL	0.6591 mL	1.6479 mL
	100 mM	0.0527 mL	0.2637 mL	0.5273 mL	1.3183 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Dopamine hydrochloride

29 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Dopamine hydrochloride

Publications Citing Use of MedChemExpress (MCE) Dopamine hydrochloride

Alle Dopamine Receptor Isoform-spezifische Produkte anzeigen

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (29)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Dopamine hydrochloride Related Classifications

HY-B0451A Related Classifications